As we count down to the beginning of the annual ADA conference it needs to be asked what’s the plan for Abbott and the future of the Libre. While the company contends that the Libre 2.0 will receive an iCGM designation as of this writing there has been nothing official from the FDA. No matter what happens with the Libre 2.0 and the FDA our question becomes why is Abbott content to basically go it alone with just one insulin delivery partner. Bigfoot their lone partner has stated they won’t even have a system on the . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.